Conquering the dark side: colloidal iron oxide nanoparticles.
about
Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers.Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agentsNanoparticles in magnetic resonance imaging: from simple to dual contrast agentsBionanotechnology and the future of glioma.Imaging and drug delivery using theranostic nanoparticlesMultifunctional agents for concurrent imaging and therapy in cardiovascular diseaseNanomedicine strategies for molecular targets with MRI and optical imaging.New simulation approach using classical formalism to water nuclear magnetic relaxation dispersions in presence of superparamagnetic particles used as MRI contrast agents.Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques.Magnetic poly(lactide-co-glycolide) and cellulose particles for MRI-based cell tracking.Carbon-coated iron oxide nanoparticles as contrast agents in magnetic resonance imaging.Superparamagnetic iron oxide nanoparticles with variable size and an iron oxidation state as prospective imaging agentsImaging of apoptosis in the heart with nanoparticle technology.Synergy between surface and core entrapped metals in a mixed manganese-gadolinium nanocolloid affords safer MR imaging of sparse biomarkers.Gas phase condensation of superparamagnetic iron oxide-silica nanoparticles--control of the intraparticle phase distribution.Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases.Prostate stem cell antigen-targeted nanoparticles with dual functional properties: in vivo imaging and cancer chemotherapy.Colorectal cancer lymph node staining by activated carbon nanoparticles suspension in vivo or methylene blue in vitro.Membrane mimetic surface functionalization of nanoparticles: methods and applicationsSuperparamagnetic Nanoparticles for Atherosclerosis ImagingMR molecular imaging of tumor vasculature and vascular targets.Magnetoliposomes as multimodal contrast agents for molecular imaging and cancer nanotheragnostics.Magnetic resonance imaging of pathological processes in rodent models of amyotrophic lateral sclerosis.Magnetite Nanoparticles for Medical MR Imaging.Emerging engineered magnetic nanoparticulate probes for molecular MRI of atherosclerosis: how far have we come?Binding patterns of homo-peptides on bare magnetic nanoparticles: insights into environmental dependence.Synthesis of NanoQ, a copper-based contrast agent for high-resolution magnetic resonance imaging characterization of human thrombus.Advantages and Limitations of Current Techniques for Analyzing the Biodistribution of NanoparticlesUltrasmall Water-Soluble and Biocompatible Magnetic Iron Oxide Nanoparticles as Positive and Negative Dual Contrast Agents
P2860
Q26830028-BDDF5CE0-88E3-4AE2-BE56-EA28F94BA183Q27027613-BD48F1DB-1769-458C-9CC4-35BA53C29537Q28082690-14056A3D-72DD-4CA0-8A7B-1588F909DD93Q30417964-ECF09CAF-B1AE-40B3-AAC1-1ECAF61A1273Q30449480-4C669F39-1A4E-488A-85BC-7F119CC95E08Q30474418-C2EA01A7-69FE-44F6-A70D-C107D955590FQ30481471-4080F51A-B97F-4BE0-B1D1-3AE7C480C11BQ30569793-F3C07AFC-E227-4023-BD58-81900D7F47A3Q33839384-DC0C0504-8295-4935-965C-510608B7F6C0Q33846155-20D1FE8D-4CF4-4986-9EFC-92DCB4F098CCQ34119640-504FFBEE-CF45-4EF5-BE21-B0FB521181CCQ34515005-E4980E8D-DFF1-4352-A081-6A38A18A4B4FQ34913604-8B722A95-D589-4D66-8148-BF8F41BF0D16Q35317271-0658F979-0E95-4728-B35C-92BB0CF90B85Q35593432-0CB662F4-62B1-4550-B56F-B9C4DC79F302Q35667247-96AA6C90-27C2-42C4-9119-BC92CBBBADF2Q36152452-02DA7A51-CAF5-4297-B907-B164C420D948Q36395401-255AC823-DC6F-4A61-9576-4876FB00CF81Q37060172-C0C6F7F6-32E5-40A3-8D8C-37E97DCB2777Q37638513-C38D20BB-E1A8-4222-A51A-82486F9D2240Q37784288-67A34F22-22AB-4AC1-8C98-1471178706F2Q37871989-C7B4D626-1C81-4E8D-8628-AEC3A10EC3D9Q37960903-350692C2-46DB-4790-900F-05B741DC5711Q37990502-0BE7B161-CBD5-431F-B109-B29D15B02342Q38020195-72997373-A25B-4D47-A84B-23004F16D62BQ42630509-FD82159C-73A9-4766-828C-8306205B3845Q42776167-A217CF98-F4F4-4376-BCEA-AAA2D742DA66Q57181636-00746486-DD5B-490F-B403-1BD1619DE79FQ57395278-75B347F3-E803-4F4C-8701-0F3230C98F2A
P2860
Conquering the dark side: colloidal iron oxide nanoparticles.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Conquering the dark side: colloidal iron oxide nanoparticles.
@ast
Conquering the dark side: colloidal iron oxide nanoparticles.
@en
Conquering the dark side: colloidal iron oxide nanoparticles.
@nl
type
label
Conquering the dark side: colloidal iron oxide nanoparticles.
@ast
Conquering the dark side: colloidal iron oxide nanoparticles.
@en
Conquering the dark side: colloidal iron oxide nanoparticles.
@nl
prefLabel
Conquering the dark side: colloidal iron oxide nanoparticles.
@ast
Conquering the dark side: colloidal iron oxide nanoparticles.
@en
Conquering the dark side: colloidal iron oxide nanoparticles.
@nl
P2093
P2860
P356
P1433
P1476
Conquering the dark side: colloidal iron oxide nanoparticles.
@en
P2093
Angana Senpan
Gregory M Lanza
Michael J Scott
Nicholas A Mauro
Patrick J Gaffney
Ralph W Fuhrhop
Samuel A Wickline
Shelton D Caruthers
P2860
P304
P356
10.1021/NN900819Y
P407
P50
P577
2009-12-01T00:00:00Z